A new head-to-head study reveals tirzepatide achieves 47% more weight loss than semaglutide in people with obesity but without diabetes, highlighting its superior effectiveness and cardiometabolic ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients in ...

Tirzepatide discontinuation was associated with reduced cardiometabolic benefits especially among patients with body weight ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference.

By Vijay Kumar MalesuA major 72-week trial shows tirzepatide leads to double-digit weight loss and greater waist reduction than semaglutide, reshaping obesity treatment strategies and offering new ...

(MENAFN- Mid-East Info) Participants achieved an average weight loss of 20.2% with tirzepatide vs. 13.7% with semaglutide In key secondary endpoints, tirzepatide was superior to semaglutide across ...

Advertisement Article continues below this ad Both drugs are part of a ... those who took Zepbound lost about 20% of their ...

In 2022, for example, Dr. Aronne led a study showing that a 72-week course of tirzepatide at its maximum dosage reduced body weight by 20.9%; a similar study published in 2021 reported a 14.9% ...

Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight and keep it off. But until now, no one had directly compared their performance in people without ...